SVB Securities initiated coverage on Prothena with a new price target
$PRTA
Biotechnology: Pharmaceutical Preparations
Health Care
SVB Securities initiated coverage of Prothena with a rating of Outperform and set a new price target of $80.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | $40.00 | Buy | Chardan Capital Markets |
| 1/30/2024 | $68.00 → $38.00 | Buy → Neutral | BofA Securities |
| 12/12/2023 | $62.00 | Buy | Deutsche Bank |
| 4/24/2023 | $80.00 | Outperform | SVB Securities |
| 1/27/2023 | $94.00 | Overweight | Piper Sandler |
| 11/4/2022 | $52.00 → $55.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 9/28/2022 | Neutral → Buy | BofA Securities | |
| 11/19/2021 | $77.00 | Market Outperform | JMP Securities |
Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million PRX012, a potential single-injection once-monthly subcutaneous treatment, is designed to address the unmet need of millions of patients with presymptomatic or early symptomatic Alzheimer's disease; Prothena expects to report multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials Results from partner Roche evaluating prasinezumab in patients with early Parkinson's disease from the Phase 2 PASA
Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million Advanced potential best-in-class Alzheimer's disease portfolio: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta/tau vaccine; Phase 2 clinical trial initiated in patients with early Alzheimer's disease for BMS-986446 (formerly PRX005) by partner Bristol Myers Squibb Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has named David Ford to a newly created position of Chief People Officer, reporting to Prothena President and Chief Executive Officer Gene Kinney, PhD. In this role, Mr. Ford will be responsible for people, culture, and human resources strategy to drive the company's vision and overall growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240304692974/en/David Ford, Chief People Officer, Prothena (Photo: Business Wire
SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
3 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
Net cash used in operating and investing activities was $47.8 million in the fourth quarter and $150.3 million for the full year of 2024; quarter-end cash and restricted cash position was $472.2 million The company expects cash guidance for the full year 2025 net cash used in operating and investing activities to be $168 to $175 million and expects to end the year with approximately $301 million in cash (midpoint) Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis being conducted under a SPA agreement with the FDA with a primary endpoint of all-cause mortality (time-to-event) at a statis
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET. The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days. T
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Oleg Nodelman will step down from Prothena's Board of Directors to create time to focus on existing and new endeavors. During his five-year tenure, Mr. Nodelman played a pivotal role in which he made significant contributions to the Company's current strategy. "I would like to thank Oleg for his contributions during the past five years. As a veteran biotechnology investor and advisor with deep roots in the biotechnology and scientific communities, Oleg shares Prothena's mission to deliver l
SCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
SCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
Chardan Capital Markets initiated coverage of Prothena with a rating of Buy and set a new price target of $40.00
BofA Securities downgraded Prothena from Buy to Neutral and set a new price target of $38.00 from $68.00 previously
Deutsche Bank initiated coverage of Prothena with a rating of Buy and set a new price target of $62.00
Net cash used in operating and investing activities was $47.8 million in the fourth quarter and $150.3 million for the full year of 2024; quarter-end cash and restricted cash position was $472.2 million The company expects cash guidance for the full year 2025 net cash used in operating and investing activities to be $168 to $175 million and expects to end the year with approximately $301 million in cash (midpoint) Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis being conducted under a SPA agreement with the FDA with a primary endpoint of all-cause mortality (time-to-event) at a statis
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET. The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days. T
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2024 financial results on Tuesday, November 12, 2024, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on November 12. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the p